Table 3 Comparison of baseline characteristics of hypertensive adults according to antihypertensive treatment
From: Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
Characteristic | Antihypertensive treatment (n = 1,044) | ACEI/ARB (n = 782) | Non-ACEI/ARB (n = 262) | P-value |
|---|---|---|---|---|
Age (yr) | 63.8 ± 14.1 | 63.0 ± 14.2 | 66.2 ± 13.6 | 0.002 |
Male sex | 525 (50.3) | 401 (51.3) | 124 (47.3) | 0.268 |
Comorbidity | ||||
Diabetes | 410 (39.3) | 333 (42.6) | 77 (29.4) | 0.002 |
Dyslipidemia | 620 (59.4) | 481 (61.5) | 139 (53.1) | 0.016 |
Chronic kidney disease | 177 (17.0) | 144 (18.4) | 33 (12.6) | 0.030 |
Chronic obstructive pulmonary disease | 181 (17.3) | 134 (17.1) | 47 (17.9) | 0.766 |
Cancer | 119 (11.4) | 80 (10.2) | 39 (14.9) | 0.040 |
Cardiovascular disease | 358 (34.3) | 261 (33.4) | 97 (37.0) | 0.282 |
Ischemic heart disease | 185 (17.7) | 137 (17.5) | 48 (18.3) | 0.769 |
Myocardial infarction | 27 (2.6) | 23 (2.9) | 4 (1.5) | 0.212 |
Stroke | 137 (13.1) | 97 (12.4) | 40 (15.3) | 0.235 |
Congestive heart failure | 163 (15.6) | 113 (14.5) | 50 (19.1) | 0.074 |
Antihypertensive treatment | ||||
ACEI | 51 (4.9) | 51 (6.5) | 0 | < 0.001 |
ARB | 744 (71.3) | 744 (95.1) | 0 | < 0.001 |
β-blockers | 183 (17.5) | 122 (15.6) | 61 (23.3) | 0.005 |
Calcium channel blockers | 593 (56.8) | 422 (54.0) | 171 (65.3) | 0.001 |
Diuretics | 223 (21.4) | 187 (23.9) | 36 (13.7) | 0.001 |
Others | 100 (9.6) | 48 (6.1) | 52 (19.8) | < 0.001 |